Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
| Company | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency  | Penalty Amount |
|---|---|---|---|---|---|---|
| GlaxoSmithKline LLC | GlaxoSmithKline | pharmaceuticals | environmental violation | 2015 | NY-ENV | $24,200 |
| AMRI Rensselaer, Inc. | Curia Inc. | pharmaceuticals | environmental violation | 2014 | NY-ENV | $45,000 |
| Mallinckrodt LLC | Mallinckrodt | pharmaceuticals | environmental violation | 2014 | NY-ENV | $7,499 |
| Abbott Laboratories | Abbott Laboratories | pharmaceuticals | consumer protection violation | 2018 | NY-AG | $50,000 |
| Abbott Laboratories, Inc. | Abbott Laboratories | pharmaceuticals | consumer protection violation | 2013 | NY-AG | $25,000 |
| Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. | Endo International | pharmaceuticals | drug or medical equipment safety violation | 2016 | NY-AG | $200,000 |
| McNeil-PPC, Inc. | Johnson & Johnson | pharmaceuticals | consumer protection violation | 2004 | NY-AG | $52,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | consumer protection violation | 2018 | NY-AG | $700,000 |
| Pharmacia Corporation | Pfizer | pharmaceuticals | False Claims Act and related | 2011 | NY-AG | $2,500,000 |
| Purdue Pharma, L.P. | Purdue Pharma | pharmaceuticals | Controlled Substances Act violation | 2015 | NY-AG | $75,000 |
| Ranbaxy Pharmaceuticals, Inc. | Sun Pharmaceuticals | pharmaceuticals | price-fixing or anti-competitive practices | 2014 | NY-AG | $150,000 |
| Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2014 | NY-AG | $150,000 |
| Dey, Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2007 | NV-AG | $670,000 |
| Purdue Frederick Company, Inc. and Purdue Pharma, L.P. | Purdue Pharma | pharmaceuticals | Controlled Substances Act violation | 2007 | NV-AG | $1,047,787 |
| Pfizer Inc. | Pfizer | pharmaceuticals | drug or medical equipment safety violation | 2014 | NV-AG | $9,500,000 |
| Mallinckrodt, Inc. | Mallinckrodt | pharmaceuticals | nuclear safety violation | 2000 | NRC | $125,000 |
| Parexel International, LLC | Parexel International | pharmaceuticals | labor relations violation | 2012 | NLRB | $253,000 |
| Amgen, Inc. | Amgen | pharmaceuticals | labor relations violation | 2011 | NLRB | $40,000 |
| Merck and Company, Inc. | Merck | pharmaceuticals | labor relations violation | 2009 | NLRB | $10,710 |
| Merck & Co., Inc. | Merck | pharmaceuticals | labor relations violation | 2008 | NLRB | $100,000 |
| Schering-Plough | Merck | pharmaceuticals | labor relations violation | 2007 | NLRB | $8,200 |
| Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | pharmaceuticals | labor relations violation | 2004 | NLRB | $50,000 |
| Advanced Medical Optics | Abbott Laboratories | pharmaceuticals | labor relations violation | 2004 | NLRB | $16,800 |
| Therasense, Inc. | Abbott Laboratories | pharmaceuticals | labor relations violation | 2003 | NLRB | $236,827 |
| MERCK SHARP & DOHME CORP | Merck | pharmaceuticals | environmental violation | 2016 | NJ-ENV | $19,000 |
| E.R. SQUIBB & SONS | Bristol-Myers Squibb | pharmaceuticals | environmental violation | 2009 | NJ-ENV | $10,000 |
| PLIVA INC | Teva Pharmaceutical Industries | pharmaceuticals | environmental violation | 2007 | NJ-ENV | $15,000 |
| PLIVA INC | Teva Pharmaceutical Industries | pharmaceuticals | environmental violation | 2006 | NJ-ENV | $7,000 |
| PLIVA INC | Teva Pharmaceutical Industries | pharmaceuticals | environmental violation | 2002 | NJ-ENV | $41,350 |
| ADVANCED STERILIZATION PRODUCTS INC | Johnson & Johnson | pharmaceuticals | environmental violation | 2023 | NJ-ENV | $13,300 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2010 | NJ-AG | $1,300,000 |
| Synthes, Inc. | Johnson & Johnson | pharmaceuticals | consumer protection violation | 2009 | NJ-AG | $236,000 |
| Johnson & Johnson, Inc. | Johnson & Johnson | pharmaceuticals | insurance violation | 2020 | NC-INS | $150,000 |
| Novo Nordisk Pharmaceutical Industries, Inc. | Novo Holdings A/S | pharmaceuticals | environmental violation | 2009 | NC-ENV | $36,836 |
| Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $15,350,000 |
| Abbott Laboratories | AbbVie | pharmaceuticals | price-fixing or anti-competitive practices | 2010 | MULTI-AG | $22,500,000 |
| AbbVie Inc. | AbbVie | pharmaceuticals | kickbacks and bribery | 2018 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,800,000 |
| Aegerion Pharmaceuticals Inc. | Amryt Pharma | pharmaceuticals | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,700,000 |
| Alpharma, Inc. | Pfizer | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $750,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
| Amgen, Inc. | Amgen | pharmaceuticals | False Claims Act and related | 2013 | MULTI-AG | $11,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $46,500,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,900,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,600,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
| Aventis Pharmaceutical Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $40,000,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $10,645,600 |
| Aventis Pharmaceuticals, Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | MULTI-AG | $1,650,000 |
| Barr Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $5,900,000 |
| Bausch & Lomb | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $17,500,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $1,100,000 |
| Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
| Cephalon | Teva Pharmaceutical Industries | pharmaceuticals | consumer protection violation | 2016 | MULTI-AG | $125,000,000 |
| Cephalon, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $7,500,000 |
| CIBA Vision | Novartis | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $5,000,000 |
| Daiichi Pharmaceutical | Daiichi Sankyo | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $4,340,100 |
| Dava Pharmaceuticals, Inc. | Endo International | pharmaceuticals | False Claims Act and related | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $11,000,000 |
| Eisai | Eisai | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $7,634,700 |
| Eli Lilly & Co. | Eli Lilly | pharmaceuticals | privacy violation | 2002 | MULTI-AG | $160,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
| Endo Health Solutions | Endo International | pharmaceuticals | False Claims Act and related | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $39,000,000 |
| Endo International plc | Endo International | pharmaceuticals | price-fixing or anti-competitive practices | 2019 | MULTI-AG | $2,300,000 |
| Genentech Inc. | Roche | pharmaceuticals | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,200,000 |
| Geneva Pharmaceuticals | Novartis | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $15,350,000 |
| Genzyme Corp. | Sanofi | pharmaceuticals | False Claims Act and related | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,280,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2003 | MULTI-AG | $40,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $10,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | MULTI-AG | $14,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2006 | MULTI-AG | $3,500,000 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | pharmaceuticals | drug or medical equipment safety violation | 2011 | MULTI-AG | $40,750,000 |
| Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
| Inspire Pharmaceuticals | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
| InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
| Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $60,000,000 |
| King Pharmaceuticals | Pfizer | pharmaceuticals | False Claims Act and related | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $124,000,000 |
| Kos Pharmaceuticals | AbbVie | pharmaceuticals | kickbacks and bribery | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,454,432 |
| Merck & Co. Inc. | Merck | pharmaceuticals | consumer protection violation | 2009 | MULTI-AG | $5,400,000 |
| Merck & Co. | Merck | pharmaceuticals | consumer protection violation | 2008 | MULTI-AG | $58,000,000 |
| Merck KGaA | Merck KGaA (EMD) | pharmaceuticals | price-fixing or anti-competitive practices | 2009 | MULTI-AG | $2,275,454 |
| Mylan Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $465,000,000 |
| Mylan Laboratories et al. | Viatris | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $108,000,000 |
| Mylan Pharmaceuticals, Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $118,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
| Novo Nordisk Inc. | Novo Holdings A/S | pharmaceuticals | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,320,963 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
| Ortho-McNeil Pharmaceutical, Inc. | Johnson & Johnson | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,400,000 |
| OSI Pharmaceuticals LLC | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,200,000 |
| Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
| Par Pharmaceuticals, Inc. | Endo International | pharmaceuticals | False Claims Act and related | 2011 | MULTI-AG | $154,000,000 |
| Perrigo Company | Perrigo | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $750,000 |
| Pfizer | Pfizer | pharmaceuticals | drug or medical equipment safety violation | 2003 | MULTI-AG | $6,000,000 |
| Pfizer | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2002 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $21,084,700 |
